Similar efficacy and safety of once‐weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years

AIMS: To evaluate the efficacy and safety of dulaglutide 1.5 and 0.75 mg in elderly patients (aged ≥65 years) with type 2 diabetes (T2D) in six phase III clinical trials. METHODS: Patients were grouped into two age groups: ≥65 and <65 years. Pooled analysis for glycated haemoglobin (HbA1c) change...

Descripción completa

Detalles Bibliográficos
Autores principales: Boustani, M. A., Pittman, I., Yu, M., Thieu, V. T., Varnado, O. J., Juneja, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089646/
https://www.ncbi.nlm.nih.gov/pubmed/27161178
http://dx.doi.org/10.1111/dom.12687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089646/
https://www.ncbi.nlm.nih.gov/pubmed/27161178
http://dx.doi.org/10.1111/dom.12687

Ejemplares similares